Olema Pharmaceuticals Competitors

Schrödinger (NASDAQ:SDGR) and Olema Pharmaceuticals (NASDAQ:OLMA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Insider & Institutional Ownership

41.3% of Schrödinger shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Schrödinger and Olema Pharmaceuticals, as reported by MarketBeat.com.

Schrödinger currently has a consensus target price of $85.50, indicating a potential upside of 15.70%. Olema Pharmaceuticals has a consensus target price of $60.6667, indicating a potential upside of 84.73%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Schrödinger.

Valuation & Earnings

This table compares Schrödinger and Olema Pharmaceuticals' top-line revenue, earnings per share and valuation.

Olema Pharmaceuticals has lower revenue, but higher earnings than Schrödinger.

Profitability

This table compares Schrödinger and Olema Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Olema Pharmaceuticals beats Schrödinger on 6 of the 8 factors compared between the two stocks.

Galapagos (NASDAQ:GLPG) and Olema Pharmaceuticals (NASDAQ:OLMA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Valuation & Earnings

This table compares Galapagos and Olema Pharmaceuticals' top-line revenue, earnings per share and valuation.

Galapagos has higher revenue and earnings than Olema Pharmaceuticals.

Analyst Ratings

This is a breakdown of current recommendations for Galapagos and Olema Pharmaceuticals, as reported by MarketBeat.com.

Galapagos currently has a consensus target price of $143.7273, indicating a potential upside of 84.72%. Olema Pharmaceuticals has a consensus target price of $60.6667, indicating a potential upside of 84.73%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Galapagos.

Insider & Institutional Ownership

11.2% of Galapagos shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Galapagos and Olema Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Olema Pharmaceuticals beats Galapagos on 5 of the 8 factors compared between the two stocks.

Olema Pharmaceuticals (NASDAQ:OLMA) and Atea Pharmaceuticals (NASDAQ:AVIR) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Earnings & Valuation

This table compares Olema Pharmaceuticals and Atea Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a summary of recent ratings for Olema Pharmaceuticals and Atea Pharmaceuticals, as reported by MarketBeat.com.

Olema Pharmaceuticals presently has a consensus price target of $60.6667, indicating a potential upside of 84.73%. Atea Pharmaceuticals has a consensus price target of $69.3333, indicating a potential upside of 22.69%. Given Olema Pharmaceuticals' higher probable upside, research analysts clearly believe Olema Pharmaceuticals is more favorable than Atea Pharmaceuticals.

Profitability

This table compares Olema Pharmaceuticals and Atea Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Olema Pharmaceuticals beats Atea Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Olema Pharmaceuticals (NASDAQ:OLMA) and Sage Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Earnings & Valuation

This table compares Olema Pharmaceuticals and Sage Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Olema Pharmaceuticals has higher earnings, but lower revenue than Sage Therapeutics.

Analyst Recommendations

This is a summary of recent ratings for Olema Pharmaceuticals and Sage Therapeutics, as reported by MarketBeat.com.

Olema Pharmaceuticals presently has a consensus price target of $60.6667, indicating a potential upside of 84.73%. Sage Therapeutics has a consensus price target of $87.0625, indicating a potential upside of 13.64%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Olema Pharmaceuticals is more favorable than Sage Therapeutics.

Profitability

This table compares Olema Pharmaceuticals and Sage Therapeutics' net margins, return on equity and return on assets.

Summary

Olema Pharmaceuticals beats Sage Therapeutics on 5 of the 7 factors compared between the two stocks.

Olema Pharmaceuticals (NASDAQ:OLMA) and Biohaven Pharmaceutical (NYSE:BHVN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Earnings & Valuation

This table compares Olema Pharmaceuticals and Biohaven Pharmaceutical's gross revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a summary of recent ratings for Olema Pharmaceuticals and Biohaven Pharmaceutical, as reported by MarketBeat.com.

Olema Pharmaceuticals presently has a consensus price target of $60.6667, indicating a potential upside of 84.73%. Biohaven Pharmaceutical has a consensus price target of $96.4545, indicating a potential upside of 39.00%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Olema Pharmaceuticals is more favorable than Biohaven Pharmaceutical.

Insider & Institutional Ownership

99.4% of Biohaven Pharmaceutical shares are owned by institutional investors. 19.1% of Biohaven Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Olema Pharmaceuticals and Biohaven Pharmaceutical's net margins, return on equity and return on assets.

Summary

Olema Pharmaceuticals beats Biohaven Pharmaceutical on 4 of the 7 factors compared between the two stocks.

Olema Pharmaceuticals (NASDAQ:OLMA) and Hutchison China MediTech (NASDAQ:HCM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Earnings & Valuation

This table compares Olema Pharmaceuticals and Hutchison China MediTech's gross revenue, earnings per share (EPS) and valuation.

Olema Pharmaceuticals has higher earnings, but lower revenue than Hutchison China MediTech.

Analyst Recommendations

This is a summary of recent ratings for Olema Pharmaceuticals and Hutchison China MediTech, as reported by MarketBeat.com.

Olema Pharmaceuticals presently has a consensus price target of $60.6667, indicating a potential upside of 84.73%. Hutchison China MediTech has a consensus price target of $40.00, indicating a potential upside of 36.80%. Given Olema Pharmaceuticals' higher probable upside, research analysts clearly believe Olema Pharmaceuticals is more favorable than Hutchison China MediTech.

Insider & Institutional Ownership

33.5% of Hutchison China MediTech shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Olema Pharmaceuticals and Hutchison China MediTech's net margins, return on equity and return on assets.